Considering that vascular endothelial growth factor and basic fibroblast growth factor, both of which are known as HBGFs, are important factors for the proliferation of vascular endothelial cells, anti-GPC1 mAb may inhibit tumor growth in vivo by blocking GPC1 as a co-receptor activity of these factors against vascular endothelial cells and inhibiting neovascularization, although further studies are required to completely elucidate this potential mechanism. The gene discussed is FGF2; the disease is neoplasm.